NASDAQ:CNMD - CONMED Stock Price, News, & Analysis

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

CONMED declared a quarterly dividend on Friday, November 9th. Investors of record on Friday, December 14th will be paid a dividend of $0.20 per share on Monday, January 7th. This represents a $0.80 annualized dividend and a yield of 1.26%. The ex-dividend date is Thursday, December 13th. View CONMED's Dividend History.

CONMED Co. (NASDAQ:CNMD) issued its quarterly earnings results on Thursday, November, 1st. The medical technology company reported $0.46 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.45 by $0.01. The medical technology company earned $202.30 million during the quarter, compared to analysts' expectations of $198.51 million. CONMED had a net margin of 8.56% and a return on equity of 9.51%. The company's revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.42 EPS. View CONMED's Earnings History.

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, January 30th 2019. View Earnings Estimates for CONMED.

CONMED updated its FY18 earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $2.15-2.20 for the period, compared to the Thomson Reuters consensus estimate of $2.17. CONMED also updated its FY 2018 guidance to $2.15-2.20 EPS.

3 equities research analysts have issued twelve-month target prices for CONMED's stock. Their predictions range from $78.00 to $83.00. On average, they anticipate CONMED's stock price to reach $80.6667 in the next twelve months. This suggests a possible upside of 26.6% from the stock's current price. View Analyst Price Targets for CONMED.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CONMED.

Media coverage about CNMD stock has trended somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CONMED earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the medical technology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

CONMED saw a decline in short interest in November. As of November 30th, there was short interest totalling 511,109 shares, a decline of 34.4% from the November 15th total of 778,547 shares. Based on an average trading volume of 136,224 shares, the days-to-cover ratio is presently 3.8 days. Approximately 1.8% of the shares of the stock are sold short. View CONMED's Current Options Chain.

Some companies that are related to CONMED include Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Fonar (FONR), Electrocore (ECOR), Zynex (ZYXI) and Stereotaxis (STXS).

CONMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.34%), Vanguard Group Inc. (9.48%), Vanguard Group Inc (9.48%), Dimensional Fund Advisors LP (6.24%), Capital Research Global Investors (6.11%) and Scopia Capital Management LP (4.28%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.

CNMD stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Victory Capital Management Inc., Dimensional Fund Advisors LP, William Blair Investment Management LLC, Alliancebernstein L.P., Fisher Asset Management LLC, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.

CNMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc., Capital Research Global Investors, Morgan Stanley, O Shaughnessy Asset Management LLC, Putnam Investments LLC and American Century Companies Inc.. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNMD stock can currently be purchased for approximately $63.74.

CONMED has a market capitalization of $1.79 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

The official website for CONMED is http://www.conmed.com.

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.